GlassScriptPhysician profile
James T Kennett
NPI 1164565784
$3,643.63
in general payments reported to CMS, 2019-2025
23 companies · $730 in 2025
The $730 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $408 · 2022: $521 · 2023: $861 · 2024: $1,124 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,714.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,226.79 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $540.08 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $497.88 | 2021-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $253.16 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $230.50 | 2021-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $151.82 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.20 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $118.05 | 2022-2025 | Farxiga, Brilinta |
| Lexicon Pharmaceuticals, INC. | $70.76 | 2023-2024 | Inpefa |
| Boston Scientific Corporation | $63.50 | 2021-2025 | Bodyguardian, Watchman Flx, Cds - Mct/Cem Monitoring |
| Pfizer INC. | $61.42 | 2022-2024 | |
| Abbott Laboratories | $43.54 | 2022-2024 | Amplatzer Talisman, Jot Dx |
| Novo Nordisk INC | $36.60 | 2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $36.44 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $32.33 | 2025 | Eliquis |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $31.19 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Esperion Therapeutics, INC. | $29.98 | 2021-2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $17.49 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $16.68 | 2023 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $15.73 | 2025 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $13.66 | 2023 | Livalo, Seglentis |
| Kiniksa Pharmaceuticals, LTD. | $12.90 | 2023 | Arcalyst |
| Amarin Pharma, INC. | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.